COVID-19 Switzerland
Information on the current situation, as of 28 March 2023
Development over time by vaccine
Hospitalisations by vaccination status, Switzerland and Liechtenstein, 27.01.2021 to 04.09.2022
The chart shows the development over time of reported laboratory-confirmed hospitalisations by vaccination status in Switzerland and Liechtenstein, broken down by vaccine.
The data shown here are based on information supplied to us by doctors and hospitals as part of the reporting obligation. They do not allow a formal comparison of the efficacy of vaccines. Interpretation of the data is limited by many factors, including the integration period of the respective vaccines in the vaccination strategy, vaccination coverage in the various specific target groups, and the predominance of a virus variant at a given time.
The data shown here are based on information supplied to us by doctors and hospitals as part of the reporting obligation. They do not allow a formal comparison of the efficacy of vaccines. Interpretation of the data is limited by many factors, including the integration period of the respective vaccines in the vaccination strategy, vaccination coverage in the various specific target groups, and the predominance of a virus variant at a given time.
In Switzerland and Liechtenstein, various vaccines are licensed for the prevention of COVID-19. A booster vaccination with an mRNA vaccine from Moderna (Spikevax® or Spikevax Bivalent Original/Omicron), Pfizer/BioNTech (Comirnaty®, Comirnaty Bivalent Original/Omicron) or the vaccine Novavax (Nuvaxovid®) is recommended no sooner than four months after the last vaccination or recovery from infection for persons 16 years and older.
The efficacy of vaccines available in Switzerland is very high. They provide some protection against symptomatic as well as asymptomatic infections and reduce the risk of transmission. In particular, they provide effective protection against severe courses of disease. However, this does not rule out the possibility that vaccinated persons (with or without booster vaccination) may become infected and ill, because no vaccine offers 100 percent protection.
We have been collecting data on vaccination status since the end of January 2021, based on information provided by physicians and hospitals as part of mandatory reporting requirements. This includes clinical information and vaccination status regarding hospitalization and deaths related to laboratory-confirmed SARS-CoV-2 infection.
The incidence data are given per 100,000 inhabitants with the corresponding vaccination status. Calculation of the proportion of persons affected refers in each case to the total population.
When assessing cases according to vaccination status, it should be noted that the vaccination strategy stipulated that older persons and those at particular risk were vaccinated earlier, and that vaccination readiness is not independent of the individual's risk of a severe course. The time frame desired can be selected with the slider below the graph.
The efficacy of vaccines available in Switzerland is very high. They provide some protection against symptomatic as well as asymptomatic infections and reduce the risk of transmission. In particular, they provide effective protection against severe courses of disease. However, this does not rule out the possibility that vaccinated persons (with or without booster vaccination) may become infected and ill, because no vaccine offers 100 percent protection.
We have been collecting data on vaccination status since the end of January 2021, based on information provided by physicians and hospitals as part of mandatory reporting requirements. This includes clinical information and vaccination status regarding hospitalization and deaths related to laboratory-confirmed SARS-CoV-2 infection.
The incidence data are given per 100,000 inhabitants with the corresponding vaccination status. Calculation of the proportion of persons affected refers in each case to the total population.
When assessing cases according to vaccination status, it should be noted that the vaccination strategy stipulated that older persons and those at particular risk were vaccinated earlier, and that vaccination readiness is not independent of the individual's risk of a severe course. The time frame desired can be selected with the slider below the graph.
Hospitalisations by vaccination status and vaccine
7-day average:
Moderna (Spikevax®), fully vaccinated
Pfizer/BioNTech (Comirnaty®), fully vaccinated
Johnson & Johnson (COVID-19 Vaccine Janssen®), fully vaccinated
Not vaccinated
Vaccine unknown, fully vaccinated
Hospitalisations
Population by vaccination status and vaccine
Moderna (Spikevax®), fully vaccinated
Pfizer/BioNTech (Comirnaty®), fully vaccinated
Johnson & Johnson (COVID-19 Vaccine Janssen®), fully vaccinated
Moderna (Spikevax®), partially vaccinated
Pfizer/BioNTech (Comirnaty®), partially vaccinated
Not vaccinated
Proportion of people